Cyclerion TherapeuticsCYCN
About: Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.
Employees: 1
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
0% more funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 1 (+0) [Q1 2025]
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
0.32% less ownership
Funds ownership: 14.1% [Q4 2024] → 13.78% (-0.32%) [Q1 2025]
5% less funds holding
Funds holding: 19 [Q4 2024] → 18 (-1) [Q1 2025]
24% less capital invested
Capital invested by funds: $1.23M [Q4 2024] → $932K (-$299K) [Q1 2025]
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Research analyst outlook
We haven’t received any recent analyst ratings for CYCN.
Financial journalist opinion



